Otsuka's Sibeprenlimab Confirms Long-Term Benefit, Shifting IgAN Battleground to Head-to-Head Differentiation

Otsuka's Voyxact Stabilizes Kidney Function in Phase III IgAN Trial

Otsuka Pharmaceutical's Voyxact (sibeprenlimab) demonstrated stabilization of kidney function over two years in patients with primary IgA nephropathy (IgAN) at risk for disease progression, as reported from the Phase III VISIONARY trial (NCT05248646). The study met its key secondary endpoint, showing an annualised estimated eGFR slope of 0.3mL/min/1.73 m²/year with Voyxact, significantly outperforming placebo which saw a 4.2mL/min/1.73 m²/year reduction. This translates to a statistically significant treatment effect of 4.5mL/min/1.73 m²/year. Voyxact, an APRIL inhibitor, previously received accelerated FDA approval in November 2025 based on a 51% reduction in proteinuria at nine months.

• The Phase III VISIONARY trial's two-year data revealed that Voyxact stabilized kidney function in IgAN patients, achieving an annualised estimated eGFR slope of 0.3mL/min/1.73 m²/year. This represents a significant 4.5mL/min/1.73 m²/year treatment effect compared to placebo, which experienced a 4.2mL/min/1.73 m²/year reduction, meeting the study's key secondary endpoint.
• Voyxact is the first IgAN treatment to achieve the KDIGO therapeutic goal of reducing kidney function decline to a near physiological rate (<1 mL/min/1.73 m²/year for most adults). The drug maintained a consistent safety profile over two years, comparable to placebo, with similar rates of overall adverse events, infections, and infestations.
• Voyxact, a selective A-PRoliferation-Inducing-Ligand (APRIL) inhibitor, received accelerated approval from the US FDA in November 2025 based on a 51% placebo-adjusted reduction in proteinuria at nine months. The IgAN market is seeing increased activity with other therapies like Vera Therapeutics' Trutakna, Novartis' Vanrafia, and Vertex's povetacicept also showing recent success.

Voyxact's VISIONARY Trial: Stabilizing IgAN Kidney Function for Two Years

A meta-analysis of recent randomized controlled trials in IgA nephropathy (IgAN) demonstrates differential efficacy across four main therapeutic classes. In terms of proteinuria reduction, corticosteroids showed the most pronounced effect (-51%), followed by B-cell modulating agents (-45%), complement inhibitors (-35%), and non-immunological therapies (-34%), with significant heterogeneity between classes (P-heterogeneity <0.001). For the preservation of renal function, B-cell modulating agents provided the largest benefit with an eGFR slope improvement of 4.3 mL/min/1.73 m²/year, followed by corticosteroids (+2.3 mL/min/1.73 m²/year) and non-immunological therapies (+1.1 mL/min/1.73 m²/year). Another analysis found complement pathway inhibitors preserved eGFR by +5.8 mL/min/1.73 m²/year. These efficacy signals translate to favorable projected hard kidney outcomes, with hazard ratios of 0.37 for systemic corticosteroids, 0.38 for novel B-cell agents, and 0.42 for novel complement agents.

Further analyses provide nuance on specific agents and safety considerations. A retrospective cohort study comparing the B-cell modulator telitacicept with budesonide EC revealed that the treatment effect on proteinuria was significantly modified by baseline levels (interaction P=0.003), with telitacicept showing a greater relative benefit in patients with mild-to-moderate proteinuria. In a separate study of patients with severe renal impairment (eGFR 15-35 mL/min/1.73 m²), telitacicept monotherapy stabilized mean eGFR over 24 months while sustaining a proteinuria reduction of 45-51%. Regarding safety, systemic corticosteroids carry the highest risk of serious adverse events (RR 3.28), whereas newer classes like B-cell modulating agents and complement inhibitors are generally well tolerated. The robust data on proteinuria and eGFR slope are critical, as these are now accepted surrogate endpoints for accelerated approval pathways in IgAN.

Understanding IgAN Progression: The Role of APRIL Inhibition

The pathogenesis of IgA nephropathy (IgAN) is recognized as a complex, heterogenous autoimmune process. The central mechanism involves the generation of circulating immune complexes containing under-glycosylated IgA1, which preferentially deposit in the glomerular mesangium. This deposition, the histopathologic hallmark of the disease, triggers a local inflammatory reaction leading to tissue injury, glomerulosclerosis, and interstitial fibrosis. The development of IgAN is influenced by a combination of genetic and environmental factors, which accounts for its notable predominance in Asian populations and rarity in individuals of African descent. Key environmental contributors to disease progression include persistent hyperglycemia, reactive oxygen species, systemic and glomerular hypertension, and dyslipidemia.

Several molecular pathways have been investigated for their role in IgAN. B-cell activating factor (BAFF), a member of the TNF family, has been proposed as a pathogenic factor due to its role in B-cell activation and IgA class switching. However, recent murine studies challenge its direct involvement in disease progression. These studies show that while BAFF inhibition significantly reduces general immunoglobulin levels, it does not impact the production of nephritogenic IgA or slow disease progression, suggesting that BAFF-dependent IgA production may not be a primary driver of IgAN pathogenesis. Further research is also exploring circulating permeability factors, circulating urokinase receptor, and mutations in complement regulatory proteins like factor H and factor I as potential predictors of disease recurrence.

The progression of IgAN to end-stage kidney disease (ESKD) is driven by a distinct set of clinical and pathological risk factors. Patients with proteinuria exceeding 1 g/day, hypertension, and impaired renal function at diagnosis are considered to have a high risk of progression. Pathological risk factors, such as specific glomerular and tubulointerstitial grades, have been identified as predictors of progression independent of clinical measurements at the time of biopsy. For instance, a low percentage of sclerosis per glomerulus (<10%) correlates with a nonprogressive disease course in early IgAN. In contrast, other findings like hyaline arteriolosclerosis and acute glomerular lesions do not appear to correlate with the rate of disease progression.

Navigating the Evolving IgAN Treatment Landscape: Voyxact's Position

The treatment landscape for IgA nephropathy (IgAN) has undergone a profound transformation over the past five years, shifting from a reliance on supportive care and non-specific immunosuppression to an era of targeted, disease-modifying therapies. This evolution, fueled by a deeper understanding of disease pathogenesis and favorable regulatory changes, has resulted in several novel drug approvals and a robust late-stage pipeline. The focus has now moved toward personalized medicine, with the goal of improving long-term renal outcomes.

• First Targeted Approvals Establish New Standard: The approval of three novel therapies—nefecon (Tarpeyo), sparsentan, and iptacopan—marks a significant milestone. Nefecon, a targeted-release formulation of budesonide, demonstrated in the Phase 3 NefIgArd trial a statistically significant and durable reduction in eGFR decline over a two-year period compared to placebo, supporting its role as a disease-modifying agent. This first wave of approved targeted therapies has fundamentally altered the treatment algorithm for patients at risk of progression.

• Endothelin Receptor Antagonists Show Promise: This class of agents has produced important late-stage clinical data. A Phase 2 trial of SC0062 showed a dose-dependent reduction in UPCR of up to 51.6% (placebo-corrected) at 24 weeks, notably without increasing the risk of peripheral edema. In the Phase 3 ALIGN trial, atrasentan narrowly missed its primary endpoint for eGFR preservation at 136 weeks (p=0.057) but showed a positive trend, including a substantial benefit in the cohort of patients concurrently treated with an SGLT2 inhibitor.

• Pipeline Focuses on B-Cell and Complement Pathways: The next wave of innovation is centered on key pathogenic mechanisms. Multiple inhibitors targeting the B-cell activating factors APRIL and/or BAFF (sibeprenlimab, atacicept, povetacicept, telitacicept) have demonstrated significant reductions in proteinuria in Phase 2 trials. Similarly, agents modulating the complement cascade, such as cemdisiran, ravulizumab, and the antisense Factor B inhibitor sefaxersen, have shown promising results in reducing proteinuria and hematuria in mid-stage studies.

• Paradigm Shifts Toward Precision and Value: The therapeutic evolution extends beyond new drugs to encompass a more sophisticated treatment strategy. This includes the adoption of individualized risk stratification using tools like the International IgA Nephropathy Prediction Tool (IIgAN-PT) and the integration of SGLT2 inhibitors as a foundational element of supportive care. Furthermore, economic value is becoming a key consideration, with cost-effectiveness analyses for nefecon suggesting it is a cost-saving intervention with concurrent QALY gains from a US commercial payer perspective.

Voyxact's Long-Term eGFR Data: A New Horizon for IgA Nephropathy

The latest two-year data from the VISIONARY trial for Otsuka's Voyxact (sibeprenlimab) represents a pivotal moment for IgA nephropathy (IgAN treatment. While the drug previously secured accelerated approval based on its ability to significantly reduce proteinuria, the new evidence of sustained kidney function stabilization over two years is a far more compelling indicator of long-term patient benefit. IgAN is a progressive disease, and the preservation of estimated glomerular filtration rate (eGFR) directly addresses the critical goal of preventing or delaying end-stage kidney disease.

Voyxact's mechanism of action, targeting A Proliferation-Inducing Ligand (APRIL), directly intervenes in the underlying immune dysregulation that drives IgAN pathogenesis. This targeted approach is a significant departure from non-specific immunosuppression, offering a more precise therapeutic strategy. The demonstration of a statistically significant treatment effect on eGFR slope, showing a minimal decline compared to placebo, strongly supports the drug's potential as a disease-modifying agent.

This robust long-term data strengthens Voyxact's position for full regulatory approval and provides a powerful differentiator in a competitive and evolving landscape. The convenience of subcutaneous administration, combined with evidence suggesting preservation of humoral immunity, could enhance patient adherence and market adoption. However, the IgAN treatment paradigm is rapidly advancing, with other APRIL/BAFF inhibitors, complement modulators, and SGLT2 inhibitors also showing promise. This necessitates careful consideration of Voyxact's optimal placement within future treatment algorithms, potentially as a foundational therapy or in combination regimens. While the eGFR stabilization is encouraging, continued monitoring for very long-term renal outcomes and potential immune-related risks associated with chronic Ig reduction will be crucial as real-world experience accumulates. Ultimately, these advancements underscore a clear trend towards precision medicine in nephrology, offering tailored, pathophysiologically driven solutions for patients with IgAN.